靶向CCR9的嵌合抗原受体T细胞治疗T细胞急性淋巴细胞白血病
T细胞急性淋巴细胞白血病(T-ALL)缺乏肿瘤特异性抗原,T细胞再生障碍毒性高。研究发现CCR9在超过70%的T-ALL病例中表达(复发/难治病例超过85%),而在正常T细胞中仅小部分(低于5%)表达。靶向CCR9的CAR-T细胞可抵抗自相残杀,在体外和体内均表现出强效抗白血病活性,即使靶抗原密度低。作者提出抗CCR9 CAR-T细胞可能成为T-ALL的高效治疗策略。
要点
- CCR9在超过70%的T-ALL病例中表达,复发/难治病例中超过85%。
- CCR9在正常T细胞中仅小部分(低于5%)表达。
- 靶向CCR9的CAR-T细胞可抵抗自相残杀,在体外和体内均有强效抗白血病活性。
核心结论
- 作者提出抗CCR9 CAR-T细胞可能成为T-ALL的高效治疗策略,可避免T细胞再生障碍和基因组工程的需求。
研究设计与样本
- 研究使用细胞系模型和患者来源的异种移植模型。
主要发现
- CCR9在超过70%的T-ALL病例中表达,包括超过85%的复发/难治病例,而在正常T细胞中仅小部分(低于5%)表达。
- 靶向CCR9的CAR-T细胞可抵抗自相残杀,在体外和体内均表现出强效抗白血病活性,即使靶抗原密度低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy of immature T lymphocytes, associated with higher rates of induction failure compared with those in B cell acute lymphoblastic leukemia. The potent immunotherapeutic approaches applied in B cell acute lymphoblastic leukemia, which have revolutionized the treatment paradigm, have proven more challenging in T-ALL, largely due to a lack of target antigens expressed on malignant but not healthy T cells. Unlike B cell depletion, T-cell aplasia is highly toxic. Here, we show that the chemokine receptor CCR9 is expressed in >70% of cases of T-ALL, including >85% of relapsed/refractory disease, and only on a small fraction (<5%) of normal T cells. Using cell line models and patient-derived xenografts, we found that chimeric antigen receptor (CAR) T-cells targeting CCR9 are resistant to fratricide and have potent antileukemic activity both in vitro and in vivo, even at low target antigen density. We propose that anti-CCR9 CAR-T cells could be a highly effective treatment strategy for T-ALL, avoiding T cell aplasia and the need for genome engineering that complicate other approaches.
引用
- Maciocia PM, Wawrzyniecka PA, Maciocia NC, et al. Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia. Blood. 2022. PMID: 35507686. doi:10.1182/blood.2021013648
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。